Table 3. Multiple logistic regression analysis including factors that are associated with the course of Graves' orbitopathy.

	Model I (TBII assay)		Model II (TSI bioassay)
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age	1.03 (0.98–1.08)	0.334	1.05 (0.99–1.12)	0.088
Smoker	3.14 (0.42–23.32)	0.263	4.80 (0.56–40.92)	0.151
Type of GD treatment
No	1		1
M	1.64 (0.20–13.55)	0.646	1.33 (0.13–13.55)	0.809
R/S	19.66 (0.39–988.73)	0.136	5.52 (0.07–461.31)	0.450
fT4	0.69 (0.39–1.20)	0.191	0.83 (0.48–1.43)	0.503
Steroid therapy	3.18 (0.78–12.94)	0.106	4.50 (0.85–23.76)	0.077
Thyroid size	1.31 (0.30–5.73)	0.721	0.73 (0.13–4.19)	0.722
TBII assay	1.14 (1.05–1.22)	0.001
TSI bioassay			1.01 (1.00–1.02)	<0.001

Abbreviations: CAS, clinical activity score; CI, confidence interval; GD, Graves' disease; M, anti-thyroid drug; OR, odds ratio; R, radioiodine treatment; S, thyroidectomy; TBII, thyrotropin-binding inhibitory immunoglobulin; TSI, thyroid-stimulating immunoglobulin.

TBII and TSI assays were entered into the models I and II, respectively.

Bold font is used to denote significant P-values. P-values <0.05 are considered to be statistically significant.